Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 607

1.

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.

2.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

3.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

4.

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.

Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.

Mol Cancer Ther. 2015 Sep;14(9):2035-48. doi: 10.1158/1535-7163.MCT-15-0143. Epub 2015 Jun 26.

5.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.

Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.

6.

Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.

Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.

Mol Cancer Res. 2013 Oct;11(10):1269-78. doi: 10.1158/1541-7786.MCR-13-0212. Epub 2013 Jun 27.

7.

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL.

J Clin Invest. 2010 Jul;120(7):2406-13. doi: 10.1172/JCI41680. Epub 2010 Jun 7.

8.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.

9.

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.

Liver Int. 2013 May;33(5):780-93. doi: 10.1111/liv.12126. Epub 2013 Mar 15.

PMID:
23489999
10.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

11.

Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.

Yu X, Li R, Shi W, Jiang T, Wang Y, Li C, Qu X.

Biomed Pharmacother. 2016 Feb;77:37-44. doi: 10.1016/j.biopha.2015.11.005. Epub 2015 Dec 12.

PMID:
26796263
12.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

13.

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL.

Clin Cancer Res. 2015 Dec 15;21(24):5588-600. doi: 10.1158/1078-0432.CCR-14-3283. Epub 2015 Aug 19.

14.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

López-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, Martin LA, Dowsett M.

Breast Cancer Res. 2014 Jun 30;16(3):R68. doi: 10.1186/bcr3683.

15.
16.

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.

Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.

Cancer Biol Ther. 2011 Jun 1;11(11):938-46. Epub 2011 Jun 1.

17.

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.

Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA.

Ann Oncol. 2007 Aug;18(8):1323-8.

PMID:
17693645
18.

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ.

Cancer Res. 2009 May 1;69(9):3955-62. doi: 10.1158/0008-5472.CAN-08-4450. Epub 2009 Apr 14.

19.

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.

Johnston SR, Martin LA, Head J, Smith I, Dowsett M.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):173-81. Review.

PMID:
15996863
20.

Supplemental Content

Support Center